Dupuytren's disease. State of the art and therapeutic perspectives;La malattia di Dupuytren. Stato dell'arte e prospettive terapeutiche

Reumatismo

Volumn 59, Issue 2, 2007, Pages 118-128

  Corrado, Addolorata ^a   Cantatore, F P ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Dupuytren's disease; Medical treatment; Percutaneous needle fasciotomy; Surgical treatment

Indexed keywords

CLOBETASOL; CORTICOSTEROID; GAMMA INTERFERON; METHYLPREDNISOLONE; VERAPAMIL;

ANKYLOSIS; APONEUROSIS; DRUG EFFICACY; DUPUYTREN CONTRACTURE; FASCIOTOMY; FINGER MALFORMATION; HUMAN; PHYSIOTHERAPY; REVIEW; SPLINTING; SURGICAL TECHNIQUE; ADULT; AGED; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; DUPUYTREN'S CONTRACTURE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 35448970584     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Burge P. Genetics of Dupuytren's disease. Hand Clin 1999; 15: 63-71.
2. Luck JV. Dupuytren's contracture: a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg 1959; 41: 635.
3. Saar JD, Grothaus P. Dupuytren's disease: an overview. Plast Rec Surg 2000; 106: 133.
4. Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin 1999; 11: 365.
5. Marora PD, McCulloch CAG. Dependence of collagen remodelling on ?-smooth muscle actin expression by fibroblasts. J Cell Physiol 1994; 159: 161.
6. Gabbiani G. Modulation of fibroblastic cytoskeletal features during wound healing and fibrosis. Pathol Res Pract 1994; 190: 851.
7. Schürch W, Seemayer T, Gabbiani G. The myofibroblast: a quarter after is discovery. Am K Surg Pathol 1998; 22: 141.
8. Skalli O, Schürch W, Seemayer T, et al. Myofibroblasts from diverse pathologic setting are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest 1989; 60: 275.
9. Kloen P. New insights in the development of Dupuytren's contracture: a review. Br J Plast Surg 1999; 52: 629.
10. Fitzgerald AMP, Kirkpatrick JJR, Naylor IL. Dupuytren's disease: the way forward? J Hand Surg (Br) 1999; 24.
11. Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell mediated response in Dupuytren's disease. Lancet 1993; 341.
12. Magro G, lanzafame S, Micali G. Co-ordinate expression of alpha5beta1 integrin and fibronectin in Dupuytren's disease. Acta Histochem 1995; 97.
13. Magro G, Lauteri F, Micali G, Paravizzini G, Travali S, Lanzafame S. Myofiobroblasts of palmar fibromatosis co-express transforming growth factor-alpha and epidermal growth factor receptor. J Pathol 1997; 181: 213.
14. Murrell GA, Hueston JT. Aetiology of Dupuytren's contracture. Aust NZJ Surg 1990; 60: 247.
15. Murrell GA. An insight into Dupuytren's contracture. Ann R Coll Surg Engl 1992; 74: 156.
16. Runalla VK, Borah GL. Cytokines, growth factors and plastic surgery. Plast Reconstr Surg 2001; 108: 719.
17. Slavin J. The role of cytokines in wound healing. J Pathol 1996; 178: 5.
18. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 2006; 122: 103.
19. Ignotz RA, Massague J. Type beta transforming growth factors controls the adipogenic differentiation of F3T3 fibroblasts. Proc Natl Acad Sci 1985; 82: 8530.
20. Dooley S, Delvoux B, Lahme B, Mangasser S, Gressner AM. modulation of transforming growth factor beta response and signalling during transdifferentiation of rat hepatic stellate cells or myofibroblasts. Hepatology 2000; 31: 1094.
21. Gressner AM. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int 1996; Suppl 54: S39.
22. Bertelli R, Valenti F, Oleggini R, et al. Cell-specific regulation of alpha1(III) and alpha2(V) collagen by TGFbeta1 in tubulointerstitial cell models. Nephrol Dial Transplant 1998; 13: 573.
23. Kagami S, Kuhara T, Yasutomo K, et al. Transforming growth factor-beta (TGF-beta) stimulates the expression of beta 1 integrins and adhesion by rat mesangial cells. Exp Cell Res 1998; 229: 1.
24. Kanzler S, Lohse AW, Keil A, et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Phisiol 1999; 276: G1059.
25. Murrell GA, Francis MJO, Bromley L. The collagen changes of Dupuytren's contracture. J Hand Surg (Br) 1991; 16: 263.
26. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1999; 1: 1349.
27. Augoff K, Kula J, Gosk J, Rutowski R. Epidermal growth factor in Dupuytren's disease. Plast Rec Surg 2005; 115: 128-33.
28. Jemec B, Grobbelaar AO, Wilson GD, Smith PJ, Sanders R, McGrouther DA. Is Dupuytren's disease caused by an imbalance between proliferation and cell death?. J Hand Surg 2006; 24B: 511-4.
29. Au-Yong ITH, Wildin CJ, Page RE. A review of common practice in Dupuytren surgery. Tech Hand Up Extr Surg 2005; 9: 178-87.
30. Dupuytren G. De la rètraction des doigts par suite d'une affection de l'aponévrose palmaire. Compte rendu de la clinique chirurgicale de l'Hotel Dieu. J Hebdo Med Chir 1831; V: 349-65.
31. Armstrong JR, Hurren JS, Logan AM. Dermofasciectomy in the management of Dupuytren's disease. J Bone Joint Surg 2000; 82B: 90-4.
32. Hall PN, Fitzgerald A, Sterne GD, et al. Skin replacement in Dupuytren's disease. J Hand Surg (Am) 1997; 22B: 193-7.
33. Tonkin MA, Burke FD, Varian JPW. Dupuytren's contracture, a comparative study of fasciectomy and dermofasciectomy in one hundred patients. J Hand Surg (Am) 1984; 9B: 156-62.
34. McFarlane RM, McGrouther DA. Complications and their management. Dupuytren's disease biology and treatment. Edimburgh: Churchill Livingstone 1990; 377-82.
35. Zemel NP. Dupuytren's contracture in women. Hand Clin 1991; 7: 107.
36. Jensen CM, Haugegaard, M, Rasmussen SW. Amputation in the treatment of Dupuytren's disease. J Hand Surg (Am) 1993; 18B:781-2.
37. Starkweather KD, Lattuga S, Hurst LC et al. Collagenase in the treatment of Dupuytren's disease: an in vitro study. J Hand Surg Am 1996; 21: 490-5.
38. Hurst LC, Badalamante MA. Nonoperative treatment od Dupuytren's disease. Hand Clin 1999; 15: 97-107.
39. McCarthy DM. The long-term results of enzymic fasciotomy. J Hand Surg (Br) 1992; 17: 356.
40. Hellstrom WJ, Bivalacqua TJ. Peyronie's disease: etiology, medical and surgical therapy. J Androl 2000; 21: 347-54.
41. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a longterm single-blind study. Urology 1998; 51: 620-6.
42. Rayan GM, Parizi M, Tomasek JJ. Pharmaclogic regulation of Dupuytre's fibroblasts contraction in vitro. J Hand Surg Am 1996; 21: 1065-70.
43. Ketchum LD, Donahue TK. The injection of nodules of Dupuytren's disease with triamcinolone acetonide. J Hand Surg (Am) 2000; 25A: 1157-62.
44. Pittet B, Rubbia-Brandt L, Desmpuliere A, et al. Effect of γ-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Plast Reconstr Surg 1994; 93: 1224.
45. Kadioglu A, Tefekli A, Koksal T, et al. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 289-93.
46. Bains W. Vasoprotective VEGF as a candidate for prevention of recurrence of fibrotic disease such as Dupuytren's contracture. Med Hypotheses 2003; 60: 793-6.
47. Lermusiaux et al. Le traitement médical de la maladie de Dupuytren. Actualité rhumatologique présentée au praticien. Paris Expansion Scientifique Française Ed 1980; 338-43.
48. Badois F, Lermusiaux JL, Massé C, Kuntz D. Le traitement non chirurgicale de la maladie de Dupuytren par aponévrotomie à l'aiguille. Rev Rhum 1993; 60: 808-13.
49. Lermusiaux JL, Lellouche H, Badois F, Kuntz D. Le traitement de la maladie de Dupuytren en 1997. Rev Rhum 1997; 64: 889-91.
50. Lermusiaux et al. Place de l'aponévrotomie percutanée à l'aiguille dans le traitement de la maladie de Dupuytren. Entretiens de Bichat Ortopedie, Paris, Expansion Scientifique Fran&aise 1995; 1222-6.
51. Lermusiaux JL, Badois F, Lellouche H. Maladie de Dupuytren. Rev Rhum 2001; 68: 542-7.
52. Duthie RA, Chesney RB. Percutaneous fasciotomy for Dupuytren's contracture. J Hand Surg 1997; 22B: 5215-22.
53. Rowley DI, Couch M, Chesney RB, et al. Assessment of percutaneous fasciotomy in the management of Dupuytren's disease. J Hand Surg 1984; 9B: 1631-4.
54. Bryan AS, Ghorbal MS. The long term results of closed palmar fasciotomy in the management of Dupuytren's contracture. J Hand Surg 1988; 13B: 2542-56.
55. Foucher G, Medina J, Navarro, R. Percutaneous needle aponeurotomy: complications and results. Chir Main 2001; 20: 206-11.
56. Luck JV. Dupuytren's contracture. J Bone Joint Surg 1959; 41A: 6356-64.
57. Rodrigo JJ, Niebauer JJ, Brown RL, et al. Treatment of Dupuytren's contracture. Long term results after fasciotomy. J Bone Joint Surg 1976; 58A: 3803-87.
58. Colville J. Dupuytren's contracture. The Hand 1983; 15: 1621-66.
59. Foucher G, Medina J, Malizos K. Percutaneous needle fasciotomy in Dupuytren disease. Tech Hand Up Extr Surg 2001; 5: 161-4.
60. van Rijssen AL, Werker PMN. Percutaneous needle fasciotomy in Dupuytren's disease. J Hand Surg 2006; in press.
61. Abbott K, Denney J, Burke FD, et al. A review of attitudes to splintage in Dupuytren's contracture. J Hand Surg (Am) 1987; 12B: 326-8.
62. Rives K, Gelbermann R, Smith B, et al. Severe contractures of the proximal interphalangeal joint in Duputren's disease: results of a prospective trial of operative correction and dynamic extension splinting. J Hand Surg (Am) 1992; 17A: 1153-9.